INXN-4001 is a non-viral, multigene plasmid designed to express three different human proteins. A unique triple-effector plasmid, INXN-4001 addresses multiple malfunctions of cardiomyocytes in patients with heart failure.
INXN-4001 is being studied clinically to assess its safety and feasibility of minimally invasive retrograde coronary sinus infusion (RCSI) in left ventricular assist device (LVAD) patients.
This first INXN-4001 clinical study is designed to evaluate the safety of INXN-4001 in LVAD patients as assessed by the incidence rate of all adverse events occurring up to six months post-treatment.
The study will also examine the ability of LVAD patients to wean from the LVAD device, their quality of life, and their overall daily activity.
INXN-4001 represents the leading program in Precigen's majority-owned subsidiary Xogenex, LLC, a company focused on the development of multi-genic biological therapies for cardiovascular disease.
Precigen is advancing the next generation of gene and cellular therapies using precision technology to target the most urgent and intractable diseases in oncology, autoimmune disorders, and emerging specialty therapy areas.
The company operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-confidence and commercialisation.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca